The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 8, 2012, Pages

  Shang, Quan ^a,b   Liu, Matthew K ^a   Saumoy, Monica ^a   Holst, Jens Juul ^c   Salen, Gerald ^a   Xu, Guorong ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Apoptosis; Bile acid; Glucagon like peptide 1; Hyperglycemia; Insulin; Plasma glucose

Indexed keywords

BILE ACID; COLESEVELAM; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MESSENGER RNA; PROTEIN; PROTEIN TGR5; SITAGLIPTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASCENDING COLON; CELL PROLIFERATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HALF LIFE TIME; HISTOLOGY; ILEUM; INSULIN BLOOD LEVEL; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; ZUCKER DIABETIC FATTY RAT;

ALLYLAMINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; BODY WEIGHT; CELL PROLIFERATION; CELL SIZE; DIABETES MELLITUS, TYPE 2; DIET; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; IN SITU NICK-END LABELING; INSULIN; INSULIN-SECRETING CELLS; KI-67 ANTIGEN; MALE; POSTPRANDIAL PERIOD; PYRAZINES; RATS; RATS, ZUCKER; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; TRIAZOLES;

EID: 84859748879     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00295.2011     Document Type: Article

References (26)

1. Batta AK, Salen G, Rapole KR, Batta M, Batta P, Alberts D, Earnest D. Highly simplified method for gas-liquid chromatographic quantitation of bile acids and sterols in human stool. J Lipid Res 40: 1148-1154, 1999.
2. Bays HE, Goldberg RB. The "forgotten" bile acid sequestrants: is now a good time to remember? Am J Ther 14: 567-580, 2007.
3. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam Hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 168: 1975-1983, 2008.
4. Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R. Absolute Bioavailability of sitagliptin, an oral dipeptidyl Peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 28: 315-322, 2007.
5. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145: 2653-2659, 2004.
6. Chen L, McNulty J, Anderson D, Liu Y, Nystrom C, Bullard S, Collins J, Handlon AL, Klein R, Grimes A, Murray D, Brown R, Krull D, Benson B, Kleymenova E, Remlinger K, Young A, Yao X. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J Pharmacol Exp Ther 334: 167-170, 2010.
7. D'Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 286: E882-E890, 2004.
8. Dumoulin V, Moro F, Barcelo A, Dakka T, Cuber JC. Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 139: 3780-3786, 1998.
9. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet cells. Diabetes Metab Res Rev 19: 115-123, 2003.
10. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylureabased therapy. Diabetes Care 31: 1479-84, 2008.
11. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
12. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
13. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168: 1531-1540, 2008.
14. Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai YL, Jin X, Misir S, Nagendran S, Abby SL. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract 16: 617-628, 2010.
15. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1 (7-36)amide is transformed to glucagon-like peptide-1-(9 -36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356-5363, 1999.
16. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tancen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78: 675-688, 2005.
17. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18: 430-441, 2002.
18. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329: 386-390, 2005.
19. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M. A G protein-coupled receptor responsive to bile acids. J Biol Chem 278: 9435-9440, 2003.
20. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596, 1995.
21. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. (2R)-4-oxo-4-[3 (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1- (2,4,5-trifluorophenyl-) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48: 141-151, 2005.
22. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, Babaya N, Itoi-Babaya M, Kaori K, Hiromine Y, Shibata M, Ogihara T. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56: 239-247, 2007.
23. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 298: 714-719, 2002.
24. Raz I, Hanefeld M, Xu L, Caria C, Willians-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as mono-therapy in patients with type 2 diabetes mellitus. Diabetologia 49: 2564-2571, 2006.
25. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol 298: G419-G424, 2010.
26. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10: 167-177, 2009.